Gimsilumab

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameGimsilumab
Drug Alias NameMORAb-022KIN-1901
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMacrophage colony stimulating factor 2 inhibitors
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationRheumatic Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMorphotek Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKinevant Sciences GmbhMorphotek Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)InflammationRheumatic Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A